Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 24 Myelodysplastic Syndromes 5 Myeloproliferative Disorders 3 Leukemia, Biphenotypic, Acute 3 Leukemia, Myeloid 2 Leukemia 2 Blast Crisis 2 Sarcoma, Myeloid 1 Neoplasms by Histologic Type 1 Myelodysplastic-Myeloproliferative Diseases 1 Leukemia, Promyelocytic, Acute 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Hematologic Neoplasms 1 Carcinoma, Hepatocellular 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Bevacizumab 35 durvalumab 23 atezolizumab 22 Nivolumab 20 lenvatinib 19 tremelimumab 16 Specimen Handling 14 Magnetic Resonance Spectroscopy 12 sintilimab 11 pembrolizumab 9 Ipilimumab 9 tislelizumab 7 Sorafenib 7 cabozantinib 5 X-Rays 5 Immunoglobulin G 5 Disulfides 5 Cyclophosphamide 5 regorafenib 4 Radiotherapy 4 Radiosurgery 4 Radiation 4 Oxaliplatin 4 Immunotherapy 4 Ethiodized Oil 4 fludarabine 3 donafenib 3 Surgical Procedures, Operative 3 Folfox protocol 3 Fluorouracil 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × Idarubicin × 90 days × Clear all

NCT03727633 2026-03-31

LIDA-BII

University Hospital, Montpellier

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡